Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines.

Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:43-62. doi: 10.1016/j.jbior.2018.05.002. Epub 2018 May 18.

PMID:
29861174
2.

Homologous Recombination Repair Factors Rad51 and BRCA1 Are Necessary for Productive Replication of Human Papillomavirus 31.

Chappell WH, Gautam D, Ok ST, Johnson BA, Anacker DC, Moody CA.

J Virol. 2015 Dec 23;90(5):2639-52. doi: 10.1128/JVI.02495-15.

3.

Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells.

Chappell WH, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Rakus D, Gizak A, Terrian D, Steelman LS, McCubrey JA.

Adv Biol Regul. 2016 Jan;60:64-87. doi: 10.1016/j.jbior.2015.10.001. Epub 2015 Oct 9. Review.

PMID:
26525204
4.

Productive replication of human papillomavirus 31 requires DNA repair factor Nbs1.

Anacker DC, Gautam D, Gillespie KA, Chappell WH, Moody CA.

J Virol. 2014 Aug;88(15):8528-44. doi: 10.1128/JVI.00517-14. Epub 2014 May 21.

5.

Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.

Sokolosky M, Chappell WH, Stadelman K, Abrams SL, Davis NM, Steelman LS, McCubrey JA.

Cell Cycle. 2014;13(5):820-33. doi: 10.4161/cc.27728. Epub 2014 Jan 9.

6.

Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.

Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M.

Curr Pharm Des. 2014;20(24):3944-57. Review.

PMID:
24138714
7.

Advances in targeting signal transduction pathways.

McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN.

Oncotarget. 2012 Dec;3(12):1505-21. Review.

8.

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA.

Cell Cycle. 2012 Dec 15;11(24):4579-88. doi: 10.4161/cc.22852. Epub 2012 Nov 27.

9.

Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Chappell WH, Abrams SL, Franklin RA, LaHair MM, Montalto G, Cervello M, Martelli AM, Nicoletti F, Candido S, Libra M, Polesel J, Talamini R, Milella M, Tafuri A, Steelman LS, McCubrey JA.

Cell Cycle. 2012 Dec 1;11(23):4447-61. doi: 10.4161/cc.22786. Epub 2012 Nov 16.

10.

Effects of ectopic expression of NGAL on doxorubicin sensitivity.

Chappell WH, Abrams SL, Montalto G, Cervello M, Martelli AM, Candido S, Libra M, Polesel J, Talamini R, Arlinghaus R, Steelman LS, McCubrey JA.

Oncotarget. 2012 Oct;3(10):1236-45.

11.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM.

Oncotarget. 2012 Oct;3(10):1068-111. Review.

12.

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Steelman LS, McCubrey JA.

Adv Biol Regul. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004. Epub 2012 Sep 16. No abstract available.

PMID:
23073564
13.

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM.

Oncotarget. 2012 Sep;3(9):954-87. Review.

14.

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM.

Curr Pharm Des. 2012;18(13):1784-95. Review.

PMID:
22394167
15.

Novel approaches to target cancer initiating cells-eliminating the root of the cancer.

McCubrey JA, Abrams SL, Umezawa K, Cocco L, Martelli AM, Franklin RA, Chappell WH, Steelman LS.

Adv Biol Regul. 2012 Jan;52(1):249-64. Review. No abstract available.

PMID:
21930143
16.

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA.

Oncotarget. 2011 Aug;2(8):610-26.

17.

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.

Cell Cycle. 2011 Sep 1;10(17):3003-15. Epub 2011 Sep 1.

18.

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.

Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA.

Oncotarget. 2011 Jul;2(7):538-50.

19.

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA.

Aging (Albany NY). 2011 Mar;3(3):192-222. Review.

20.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.

Oncotarget. 2011 Mar;2(3):135-64. Review.

21.

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM.

J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. Review.

PMID:
21302297
22.

Targeting the cancer initiating cell: the Achilles' heel of cancer.

McCubrey JA, Chappell WH, Abrams SL, Franklin RA, Long JM, Sattler JA, Kempf CR, Laidler P, Steelman LS.

Adv Enzyme Regul. 2011;51(1):152-62. doi: 10.1016/j.advenzreg.2010.09.002. Epub 2010 Oct 28.

PMID:
21035484
23.

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA.

Cell Cycle. 2010 May;9(9):1781-91. Epub 2010 May 10.

24.

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.

Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA.

Cell Cycle. 2010 Apr 15;9(8):1629-38. Epub 2010 Apr 15.

25.

Emerging MEK inhibitors.

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.

Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23. doi: 10.1517/14728210903282760. Review.

PMID:
20151845
26.

Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair M, Ferland RA, Steelman LS.

Adv Enzyme Regul. 2010;50(1):285-307. doi: 10.1016/j.advenzreg.2009.10.016. Epub 2009 Nov 4. Review. No abstract available.

27.

Emerging Raf inhibitors.

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.

Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Review.

PMID:
19715444
28.

Akt as a therapeutic target in cancer.

Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA.

Expert Opin Ther Targets. 2008 Sep;12(9):1139-65. doi: 10.1517/14728222.12.9.1139 . Review.

PMID:
18694380
29.

Targeting prostate cancer based on signal transduction and cell cycle pathways.

Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA.

Cell Cycle. 2008 Jun 15;7(12):1745-62. Epub 2008 Jun 16. Review.

30.

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS.

Adv Enzyme Regul. 2008;48:113-35. doi: 10.1016/j.advenzreg.2008.02.006. Epub 2008 Feb 21. No abstract available.

31.

Distinct roles for p107 and p130 in Rb-independent cellular senescence.

Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA, Terrian DM.

Cell Cycle. 2008 May 1;7(9):1262-8. Epub 2008 Mar 7.

32.

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA.

Oncogene. 2008 Jul 3;27(29):4086-95. doi: 10.1038/onc.2008.49. Epub 2008 Mar 10.

33.

Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells.

Lee JT, Steelman LS, Chappell WH, McCubrey JA.

Cell Cycle. 2008 Mar 1;7(5):631-6. Epub 2007 Dec 6.

PMID:
18256541
34.

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM.

Adv Enzyme Regul. 2007;47:64-103. Epub 2007 Mar 26. No abstract available.

35.

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM.

Cell Cycle. 2007 Mar 1;6(5):595-605. Epub 2007 Mar 18.

PMID:
17351335
36.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

37.

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA.

Leukemia. 2006 Jul;20(7):1254-60. Epub 2006 Apr 27.

PMID:
16642049
38.

Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1.

Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE.

Cell Cycle. 2005 Oct;4(10):1389-95. Epub 2005 Oct 13.

PMID:
16096376

Supplemental Content

Loading ...
Support Center